JPWO2021048822A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021048822A5 JPWO2021048822A5 JP2022516270A JP2022516270A JPWO2021048822A5 JP WO2021048822 A5 JPWO2021048822 A5 JP WO2021048822A5 JP 2022516270 A JP2022516270 A JP 2022516270A JP 2022516270 A JP2022516270 A JP 2022516270A JP WO2021048822 A5 JPWO2021048822 A5 JP WO2021048822A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- administration
- use according
- subject
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 230000036470 plasma concentration Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000032140 Sleepiness Diseases 0.000 claims 3
- 206010041349 Somnolence Diseases 0.000 claims 3
- 230000036626 alertness Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000037321 sleepiness Effects 0.000 claims 3
- -1 (4-phenylcyclohexyl)oxy Chemical group 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 208000035959 Narcolepsy type 1 Diseases 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000004461 narcolepsy 1 Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 208000001573 Cataplexy Diseases 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000003874 central nervous system depressant Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- UXZAJSZFFARTEI-GUMHCPJTSA-N methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate Chemical compound COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1COC1CCC(CC1)c1ccccc1 UXZAJSZFFARTEI-GUMHCPJTSA-N 0.000 claims 1
- UXZAJSZFFARTEI-UHFFFAOYSA-N methyl 3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate Chemical compound CS(=O)(=O)NC1C(N(CCC1)C(=O)OC)COC1CCC(CC1)C1=CC=CC=C1 UXZAJSZFFARTEI-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900298P | 2019-09-13 | 2019-09-13 | |
| US62/900,298 | 2019-09-13 | ||
| US202063031686P | 2020-05-29 | 2020-05-29 | |
| US63/031,686 | 2020-05-29 | ||
| PCT/IB2020/058483 WO2021048822A1 (en) | 2019-09-13 | 2020-09-12 | Tak-925 for use in treating narcolepsy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547711A JP2022547711A (ja) | 2022-11-15 |
| JPWO2021048822A5 true JPWO2021048822A5 (https=) | 2023-09-20 |
| JP2022547711A5 JP2022547711A5 (https=) | 2023-09-20 |
Family
ID=72560858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516270A Pending JP2022547711A (ja) | 2019-09-13 | 2020-09-12 | ナルコレプシーの治療に使用するためのｔａｋ－９２５ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220339143A1 (https=) |
| EP (1) | EP4028004A1 (https=) |
| JP (1) | JP2022547711A (https=) |
| KR (1) | KR20220062012A (https=) |
| CN (1) | CN114980892A (https=) |
| AU (1) | AU2020346456A1 (https=) |
| BR (1) | BR112022004587A2 (https=) |
| CA (1) | CA3154321A1 (https=) |
| CO (1) | CO2022004596A2 (https=) |
| MX (1) | MX2022003018A (https=) |
| WO (1) | WO2021048822A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220062361A (ko) * | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| AU2021205892B2 (en) | 2020-01-10 | 2026-04-23 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 |
| CN116583502A (zh) | 2020-09-03 | 2023-08-11 | 欧瑞夏治疗有限公司 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| US20240165092A1 (en) * | 2021-04-02 | 2024-05-23 | Takeda Pharmaceutical Limited Company | Use of an orexin 2 receptor agonist for post operation recovery |
| IL316468A (en) | 2022-04-22 | 2024-12-01 | Teijin Pharma Ltd | The aftermath of oxazepine |
| WO2024075825A1 (ja) | 2022-10-07 | 2024-04-11 | キッセイ薬品工業株式会社 | シクロペンタン化合物 |
| EP4611745A1 (en) * | 2022-10-31 | 2025-09-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| TW202535890A (zh) | 2023-10-20 | 2025-09-16 | 日商帝人製藥股份有限公司 | 氧氮呯衍生物之結晶或其溶劑合物之結晶 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025229493A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| PT929574E (pt) | 1996-08-27 | 2005-11-30 | Praecis Pharm Inc | Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos |
| EP1196609A2 (en) | 1999-06-28 | 2002-04-17 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
| MX376164B (es) * | 2014-10-23 | 2025-03-07 | Eisai R&D Man Co Ltd | Composiciones y metodos para tratar el insomnio. |
| WO2016201373A1 (en) * | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| LT3984994T (lt) * | 2016-02-04 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti |
-
2020
- 2020-09-12 AU AU2020346456A patent/AU2020346456A1/en not_active Abandoned
- 2020-09-12 BR BR112022004587A patent/BR112022004587A2/pt unknown
- 2020-09-12 WO PCT/IB2020/058483 patent/WO2021048822A1/en not_active Ceased
- 2020-09-12 EP EP20775077.9A patent/EP4028004A1/en not_active Withdrawn
- 2020-09-12 US US17/642,331 patent/US20220339143A1/en not_active Abandoned
- 2020-09-12 CN CN202080073637.7A patent/CN114980892A/zh active Pending
- 2020-09-12 CA CA3154321A patent/CA3154321A1/en active Pending
- 2020-09-12 JP JP2022516270A patent/JP2022547711A/ja active Pending
- 2020-09-12 MX MX2022003018A patent/MX2022003018A/es unknown
- 2020-09-12 KR KR1020227011013A patent/KR20220062012A/ko active Pending
-
2022
- 2022-04-11 CO CONC2022/0004596A patent/CO2022004596A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002316582B2 (en) | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic | |
| AU702106C (en) | Use of carbazole compounds for the treatment of congestive heart failure | |
| US5807571A (en) | Transdermal therapeutic systems for administering indole serotonin agonists | |
| JP2003503450A5 (https=) | ||
| JP2011514379A (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JPWO2021048822A5 (https=) | ||
| JP2009067806A (ja) | 眼の痛みを治療するためのκオピオイド・アゴニストの局所使用 | |
| EP4034156A1 (en) | Combination therapy with cgrp antagonists | |
| JP2007506752A (ja) | 肺動脈高血圧症を治療するための併用療法におけるイロプロスト | |
| US20200383983A1 (en) | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo | |
| KR20070083826A (ko) | 우울증을 위한 부가 요법 | |
| US20220125791A1 (en) | Novel devices | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2021001221A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| EP0205492A1 (en) | Analgesic, anti-inflammatory and skeletal muscle relaxant compositions | |
| JP2011512399A (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| CZ289395A3 (en) | Transdermic therapeutic system for administration of serotonin agonists | |
| KR960700696A (ko) | 정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions) | |
| MXPA02005380A (es) | Tratamiento de combinacion para trastornos del sueno, incluyendo la apnea del sueno. | |
| RU2192252C2 (ru) | Применение прамипексола в лечении синдрома усталых ног | |
| JP3007992B2 (ja) | （ｒ）−アムロジピンによる平滑筋細胞の遊走の抑制 | |
| JPWO2021048821A5 (https=) | ||
| NL8002041A (nl) | Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel. | |
| JP2002541190A (ja) | 気分障害治療用医薬を製造するためのオサネタントの使用 | |
| JPH08504203A (ja) | パーキンソン病およびその進行を治療する薬剤の製造のためのイダゾキサンおよびその誘導体の使用 |